582nd MEETING, ST. ANDREWS 651 at 250nm and/or bound cadmium. Thus the presence of cadmium-metallothionein in the liver cytoplasm of these animals seems unlikely.
Several vitamins play a n important role in hepatic oxidative metabolism. Vitamin A deficiency in rats significantly decreases microsomal protein and oxidative enzymes. Vitamin A decreases, and deficiency enhances, the carcinogenic properties of certain chemicals. Large doses of vitamin A are toxic and tend to destabilize membranes. 5-Fluorouracil is used either alone, or in combination with other drugs, in the treatment of metastatic cancer, but as with all cytotoxic drugs the margin between therapeutic and toxic doses is small.
In the present study female Wistar albino rats (200g body wt.) were given an intraperitoneal injection of 5-fluorouracil on 3 consecutive days. Blood and liver samples were taken on day 4. Thompson et al. (1971) . Table 1 shows that the human therapeutic dose of 15mg/kg body wt. decreased the haematocrit and caused a slight decrease in liver and plasma vitamin A concentrations.
At the higher doses both liver weight and terminal body weight were greatly decreased. The animals had diarrhoea, and the haematocrit increased with the loss of body fluid.
Both liver and plasma vitamin A concentrations were elevated, but in each case the increase was greater than could be accounted for by the decrease in liver weight or loss of body fluid. The amount of vitamin A per whole liver was decreased significantly in 15 mg/kg-dose group and significantly increased in the other groups. We conclude that 5-fluorouracil affects vitamin A concentrations in plasma and liver by some action that is not directly related to its cytotoxic action.
Evidence is accumulating that the nutritional status of the patient may be important in the control and treatment of cancer. A cytotoxic drug such as 5-fluorouracil may upset this balance in a way that diminishes the effectiveness of treatment. Thus it may prove necessary to monitor vitamin concentrations and dietary status during cancer treatment in order to obtain the best possible response. Phenol is largely excreted as glucuronide and sulphate conjugates in mammalian species (Capel et a/., 1972; Mehta et a/., 1978) . Few studies on glucuronidation in vitro use phenol as an acceptor substrate, as no simple assay procedure has been available. The procedure presented here is an adaptation of that described by Lucier et a / . (1971) for measuring the glucuronidation of I-naphthol.
The standard incubation medium consisted of: 0.2m~-['~C]phenol (diluted with unlabelled phenol to approx. 0.9mCi/mmol before addition), 2.7 mM-UDP-glucuronic acid, 66m~-Tris/HCI buffer, pH7.4, 10mM-MgZ+ and up to 0.05ml of microsomal fraction; total volume 0.3ml. Microsomal fraction was prepared from a 30% (w/v) rat liver homogenate in 0.25 ~-sucrose/O.O5 M-Tris/HCI (pH 7.4) by differential centrifugation (Illing et al., 1977) . The reaction was stopped after 5 or IOmin by addition of lOml of 1.5 % (w/v) 5-(biphenyl-4-yl)-2-(4-t-butylphenyl)-l-oxa-3,4-diazole in toluene.
The mixture was shaken and transferred to a scintillation vial for radioactivity counting in a liquid-scintillation counter. An external-standard channels-ratio technique (Johnson et a/., 1972) was used for quench correction.
